Still no weight loss at week 5 on Mounjaro? Here's how to think about it

Why the 2.5mg starting dose is unlikely to show much yet

The first four weeks of Mounjaro are spent at 2.5mg. That dose exists almost entirely to let your body adapt, reducing the nausea, stomach discomfort and digestive effects that can otherwise make starting difficult. It is not the dose at which significant appetite suppression typically takes hold. At week 5, many people are still on 2.5mg, or have only just moved to 5mg.

This matters because appetite and energy intake are the main levers tirzepatide pulls to produce weight loss. If appetite hasn't shifted noticeably yet, weight loss will reflect that. The tirzepatide treatment overview sets out how the dual GIP and GLP-1 mechanism builds its effect as the dose increases. Clinical trial results reported in the New England Journal of Medicine were recorded over 72 weeks, not six. Expecting significant change at week 5, while understandable, is asking for a result that even the trial design wasn't built to measure at that point.

One misconception worth naming and setting aside: a common belief is that if the medicine is 'working', the scales will move within days. For many people they do not, and that isn't a sign of treatment failure. The mechanism is gradual and cumulative.

What else can hold the scales still in the early weeks

Several things that have nothing to do with whether tirzepatide is active can keep your weight flat or even push it up slightly in the first weeks. Water retention shifts with dietary changes, particularly if carbohydrate intake falls and then fluctuates. Constipation, which is a reported side effect of GLP-1 and dual-agonist medicines, can account for a kilogram or two on the scales at any given point, and then resolve. If you have started moving more (which some people do as energy improves), you may be building or maintaining muscle while losing fat, and muscle is denser.

Scale weight is also sensitive to when you weigh yourself, hydration, and the day of your menstrual cycle if that applies to you. Weighing at the same time each week, in the morning before eating, on the same surface gives the most comparable numbers. Even then, weekly snapshots have noise. A four-week trend is more meaningful than any single reading.

For a broader picture of how week-by-week progress typically looks across the first couple of months, the Mounjaro weight loss by week guide gives a realistic breakdown. It's worth checking before drawing conclusions from a single week's number.

When no movement at week 5 is a signal worth discussing

Most of the time, stillness at week 5 is a waiting game. But there are situations where raising it with your prescriber makes sense sooner rather than later.

If your appetite has not changed at all (if you are eating the same volume and types of food as before starting) that is worth flagging. Some people need a faster dose increase, and some need a prescriber to check whether something else is affecting the medicine's absorption. Similarly, if you have experienced significant side effects that led you to take less than the prescribed dose, or to delay doses, that can interrupt the expected pattern. The early-weeks plateau guide covers some of the same ground for people who saw nothing in weeks 1–2 either.

If you are on tirzepatide privately and want to discuss your progress, our clinical team reviews every repeat order before dispensing, that check-in is a natural point to raise questions. You can also reach us through our support team, seven days a week.

For context on what NICE considers a meaningful timeframe for reviewing progress (and where private treatment fits within that) the cost and value overview touches on what a full clinical programme includes.

How to think about the decision now

The core question at week 5 with no weight loss is really two questions: is this normal timing, and am I doing everything that supports the medicine? On timing, five weeks at a starter or low dose is early. The data from large trials and the eight-week outcomes picture both suggest that most measurable loss comes after sustained dose increases.

On supporting factors: tirzepatide works alongside a reduced-calorie diet and increased physical activity, not instead of them. The NHS tirzepatide medicines page notes this clearly, and it is part of the licence. If appetite suppression hasn't kicked in enough to change eating patterns yet, actively maintaining some dietary structure still matters.

If you are also weighing up whether this is the right treatment for you at all, the weight-loss treatments overview lays out the options side by side. And if week 5 has passed and nothing has shifted by week 8 or so, realistic per-week expectations can help you assess whether to speak to a prescriber about your dose progression.

At the end of this, if you would like a clinical conversation now rather than waiting, our prescribers are available. Speak to our prescribers through a free consultation and raise exactly where you are, week 5, no loss, and the full picture of how things have gone so far. That is the most useful next step if reading hasn't settled your thinking.